Sie sind auf Seite 1von 20

newsletter

the official newsletter for members of the EHA

November 2008

EHA New
Newsletter MayStates
Jersey, United 2007 Marc2Rudoltz
by >
President’s Message:
Education in hematology:
the annual congress and more
In this issue we look back at the 13th Congress in Copenhagen. We are happy

to announce that the congress yielded a record number of participants, over

6,600, and its program was of highest scientific and educational quality. This

success is largely due to the efforts of the Scientific Program Committee

(SPC) and its Advisory Board (SPC AB), which I would like to thank for

fulfilling their tasks so proficiently. Also, I would like to thank the sponsors

for their contribution to make the congress possible. I believe that a creative

collaboration with pharmaceutical partners is essential for positive

developments in any field of medicine.

>  We also look forward. The prepara- and has developed training online (EHA-
tions for the 14th Congress in Berlin are Tol). What EHATol exactly is, is explained
in full swing. To enlighten you on how the in this issue by Gina Zini, who, together Willem Fibbe
educational and scientific program of the with the EHA executive office, shows
annual congress is put together, Radek great dedication in making available five and skills across Europe. The results will
Skoda has written a very informative ar- self-evaluation tests every three months. serve to target the gaps with existing and
ticle about the SPC and the SPC AB. I kindly invite you to take these tests novel educational tools. In addition, H-
yourself. Furthermore, plans are under Net will develop an online portfolio sys-
The annual congress of EHA is one, al- way to have the webcasts themselves tem which identifies educational needs
beit important, instrument to promote CME accredited and to extend the web- of individual hematologists and offers
education and lifelong learning in hema- casts to the workshops. In the end, the suggestions to meet them. In coordinat-
tology. For instance, EHA would like to goal is to combine these learning tools ing H-Net, EHA reinforces its dedication
reach out to those who are unable to into a blended learning experience. to arrive at a truly harmonized curricu-
come to the annual congress. Also, de- lum for European hematologists, raising
spite our efforts to arrive at a compre- Another aspect of education concerns competence levels and, ultimately, im-
hensive and well balanced educational not so much how we learn, but what we proving patient care and public health. I
program at the annual congress, not all learn. Recently, the European Commis- encourage you to read Eva Hellström-
topics in the field of hematology can be sion has awarded a network of European Lindberg’s contribution to this issue
covered. Here, I would like to focus on national societies of hematology, the Eu- which describes the grant application
those instruments that may be a little ropean School of Haematology (ESH), the process and the details of the H-Net’s
less known to you. Universities of Uppsala and Liverpool, ambitions.
and EHA a grant of up to € 600,000. The
To achieve greater outreach and to cover network’s name is H-Net and it aims to Willem Fibbe
niche topics EHA organizes two-day tu- further develop the European Hematolo- EHA President
torials and workshops, it webcasts its gy Curriculum by identifying and mea-
annual congress’ educational sessions, suring gaps in hematological knowledge

2 > EHA Newsletter November 2008


The makings of the European hematologist:
H-Net
“Yes, we can!” Echoing Barack Obama’s primary campaign slogan, Nancy Hamilton proposals issued by the directorate gen-
eral Training and Education of the Euro-
and Thom Duyvené de Wit of the EHA Executive Office responded to my question. pean Commission. We applied for a
Leonardo da Vinci network grant in the
It was over lunch at the January 23, 2008 board meeting in Amsterdam that I asked Lifelong Learning Program. The aim of
H-Net is to further implement a harmo-
if the EHA Executive Office has the capacity to make a European Commission nized curriculum for Hematology in Eu-
rope. The core of the project consists of
application for a grant to promote the implementation of the Curriculum Passport. two phases. First, a survey will be under-
taken of recently graduated hematolo-
The deadline for submission was, however, February 29, 2008. gists to assess their qualifications, then
the results will be compared to the rec-
>  In 2005 the national societies of he- responsibility for different sections, ommendations expressed in the Curricu-
matology in Europe, the European School allowing trainees to receive part of their lum Passport. The survey should allow
of Haematology (ESH) and EHA jointly education in one country, and part some- H-Net to identify gaps in hematology
developed the European Hematology where else. training throughout Europe. For instance,
Curriculum. The Passport is a booklet we may observe that in country A, re-
designed for hematologists in training to To cut a long story short, the strenuous spondents score below the recommen-
check off subjects within the specialty, efforts (and nocturnal working practices) dations with respect to their knowledge
and the level mastered (ranging from of D Jasmin of ESH, of C Hok-Toh, P Re- and competence in the area of bone mar-
awareness to competence). The trainee’s bulla, A Urbano, and L Degos of the EHA row failure while in country B respon-
mentor confirms completion of each curriculum committee, and of C Smand dents consistently achieve low scores in
subject with a signature. and the others of the EHA Executive Of- the diagnosis of immunophenotyping by
fice made the impossible possible. Final- flow cytometry. Such information, sum-
The Curriculum Passport aims to pro- ly, a night taxi ride to the headquarters marized in a “European expression map
mote the harmonization of qualifications of DHL near Amsterdam airport secured for competence in hematology”, would
and the mobility of hematologists the all important date-stamp - February enable informed decision making. Na-
throughout Europe. Harmonization was 29, 2008. tional societies, national authorities, and
achieved after the national societies of individuals themselves, can decide on
hematology, ESH, and EHA, agreed on The application we sent that night was targeted additional education. Converse-
what constitutes a hematologist. The named ‘European Network for Harmoni- ly taking into account their national con-
Curriculum Passport also promotes mo- sation of Training in Haematology’; H- text, countries may decide against ad-
bility, since different mentors can take Net. It was sent in response to a call for dressing situations they feel are not

Contents
President’s Message 2 SPC and SPC AB 11

H-Net 3 13th Congress 12

Translational research 4 Collaboration ESH-EHA 15

EHATol 5 Letter to the Editor 16

Editorial: Collaboration with pharma 6 Overview EHA Committees an Units 17

Scientific Working Groups 7 Current members of the EHA Board of Directors 18

Young investigator award 9 Upcoming congresses 18

Wine and health 12 EHA Executive Office 19

EHA Newsletter November 2008 > 3


relevant to their population. In Nordic own qualifications which will be com- conferences to bring together the na-
countries, for example, awareness rath- pared to the recommendations of the tional authorities and the European
er than competence may be considered Curriculum Passport allowing personal Commission to discuss the road map
adequate for thalassemia major. In es- gaps to be identified. The Hematology towards a harmonized curriculum for
sence, H-Net survey results would en- Portfolio will then automatically make hematology and, possibly, other medi-
able decision making to be based on fact training suggestions specific to the indi- cal specialties.
rather than assumption, and allow com- vidual educational needs of the hematol-
parisons to be made against European ogist, which may be workshops, tutori- Friday June 13 - the second day of the
benchmarks. In the second phase H-Net als, training opportunities organized by 13th EHA Congress in Copenhagen -
will use the information to tailor existing third parties, or recommendations from turned out to be our lucky day. The Euro-
educational tools, such as workshops, other portfolio holders. Ultimately, the pean Commission couldn’t have chosen
tutorials, and webcasts. The results will portfolio system should become a widely a better moment to inform us that our
also be used to develop a new education- used professional network of hematolo- application had passed the evaluation:
al instrument called the Hematology gists throughout Europe. most of the people who worked on the
Master-Class, to fit the educational project were there, so we managed a cel-
needs of hematologists and organize With the European Commission aiming ebration drink, or two.
them in the countries where they are to promote mobilization of health profes-
most needed. sionals and improve competence across Now, the hard work starts in earnest,
the board, the H-Net project undoubtedly and all involved are very excited be-
Furthermore, as part of H-Net individual has implications that go beyond hema- cause H-Net provides us with the op-
hematologists will be able to create on- tology. Currently health education orga- portunity to work together again on an
line personal profiles, known as the He- nization and content remain a national interesting and important project. I
matology Portfolio, not unlike those of prerogative, with the European Commis- hope, having read this article that you
network websites, such as LinkedIn, sion having no jurisdiction. The Commis- will agree.
MySpace, or FaceBook. sion realizes that harmonization of quali-
fications will only take place if European Eva Hellström-Lindberg, EHA Past President
In the portfolio applications, which are professionals themselves convince their and Chair of the EHA Curriculum Committee
being developed by the University of Upp- national authorities of the need for edu- Karolinska University Hospital, Stockholm,
sala Learning Lab, one of the partners of cational reform. H-Net plans to meet Sweden
H-Net, hematologists can enter their this challenge by organizing two policy

Translational research boost for Europe


A scheme to create a new training program in translational research, tions and scientific paper writing will
be planned. Participants will bring
encompassing both malignant and non-malignant hematology is currently their own translational research pro-
posals as part of the application pro-
being planned in a joint initiative between the EHA and American Society of cess for the TRTH program. These pro-
posals will be discussed in interactive
Hematology (ASH). The Translational Research Training in Hematology (TRTH) sessions, with the goal of improving
the quality of grant submissions. Op-
program is intended to boost standards of translational research in Europe, portunities for “sustained mentoring”
will be offered at follow up sessions
an area that has been identified as under resourced. scheduled to coincide with the EHA and
ASH annual meetings.

>  The TRTH program, first proposed medical students, is for participants to Issues that still remain to be resolved in-
at the 2006 ASH-EHA leadership meet- attend a six day residential course. clude eligibility for participation and re-
ing, in Orlando, Florida, is currently be- Subjects likely to be covered in the view of the applications. Another impor-
ing planned along similar lines to the ‘bench to bedside’ course include, di- tant open item is funding of the scheme.
ASH Clinical Research Training Institute, agnostics, bio banking, bio statistics, We will keep you posted as this exciting
a program that focuses on Phase I and II bio informatics, candidate gene testing initiative unfolds.
clinical trials. and stem cell research. In addition, EU
legislation, rules, directives and guide- Ivo Touw, Co-Chair TRTH Subcommittee
The proposed format of the TRTH pro- lines related to good clinical practice Erasmus Medical Center, Rotterdam,
gram, which is being targeted at clini- will be discussed, and sessions cover- The Netherlands
cians, translational scientists and bio- ing issues relevant to grant applica-

4 > EHA Newsletter November 2008


EHATol distance learning tool
gains popularity
>  In 2006 EHA launched an innovative
new project, EHA Training Online (EHA-
Tol) for scientists and clinicians involved
in the field of hematology. EHATol is an
online distance learning tool, providing a
readily accessible and constantly updat-
ed content for training, education, and
CME, with clinical cases presented and
the opportunity for on-line self assess-
ment.

What is a Clinical Case?


Each clinical case, consisting of 14-19
chapters begins with the disease history,
followed by descriptions of clinical ex-
aminations, blood tests, cytogenetics and
other diagnostic studies. The diagnosis
and treatment recommendations are
then described. The EHATol unit met in Copenhagen
According to the latest statistics, each
clinical case was visited by an average of points per year by correctly completing Join now!
143 users. the self-evaluation tests. Every three month a new set of the self
assessment cases will become available
What is a CME Test Case? EHATol is becoming increasingly popu- online.
There are three parts to a CME Test Case lar, with more than 4000 users from 60 EHATol is free of charge and available on
-the introduction- (history of the disease), different countries having already updat- the EHA website. If you would like to get
questions and results. Each self-evaluation ed their knowledge using the EHATol access to clinical and CME Test cases
test comprises six multiple choice ques- platform. please register via www.ehatol.org.
tions, with users allowed three attempts to
respond correctly to all six questions in or- The number of visitors in the first three Prof. Gina Zini, MD
der to earn one CME credit point. quarters of 2008 increased by more then Chair of the EHATol Unit
30 per cent compared to the same period Catholic University of Sacred Heart,
In August 2008 we extended the number in 2007 (see figure 2). Rome, Italy
of self assessment tests available, with
each set now including five cases. The In addition, the average length of ses-
result is that users of the EHATol plat- sions and the number of connections
form may now earn up to 20 CME credit made each day, increased significantly.

Figure 1 Figure 2: number of visitors of EHATol

EHA Newsletter November 2008 > 5


Collaborations with the
pharmaceutical industry
‘The proper basis for a marriage is mutual misunderstanding!’ Oscar Wilde.

>  There has always been a symbiosis between the pharma- be beneficial, and if the regulator releases new drugs without
ceutical industry and the medical profession. Although certain- adequate testing they are admonished for not protecting pa-
ly not a marriage, the relationship possesses similar qualities, tients!
despite the fact that neither party can ever truly divorce! The Drug costs are now a huge issue for society, especially when
protagonists come from different backgrounds but share simi- linked to efficacy. It is quite amazing when a number of drugs
lar desires. The loyalty of the pharmaceutical companies is to with similar modes of action, but different development histo-
satisfy their shareholders, while the primary role of physicians ries, are similarly priced without any regard to their research
is to provide the best medical care for their patients. Pharma- and development costs!
ceutical companies are, of course, in the business of manufac- Tyrosine Kinase inhibitors (TKI’s) are examples of drugs which
turing drugs which benefit patients, and physicians depend on have totally changed the outlook for patients with Chronic My-
the industry to develop new and effective compounds. eloid Leukemia (CML). However this disease has been trans-
Dr M Greaves, from the University of Aberdeen, addressed both formed into a chronic illness and thus patient numbers are ac-
the possible tensions and opportunities for collaboration at the cumulating. It is estimated that in the USA there soon will be
EHA annual meeting in June 2008. He began by quoting David 250,000 patients alive with CML, representing an annual cost
Blumenthal’s statement from the New England Journal of somewhere in the region of € 7,5 billion for TKI’s. While the
Medicine: ‘when a great profession and the forces of capitalism FDA does not take cost into account, countries – for example
interact, drama is the likely result’. He pointed out that re- the UK - restrict new agents on the basis of cost-effectiveness,
search and development is declining in the industry due to a often resulting in a public outcry!
combination of patent expiration and generic competition, to- With other expensive drugs, efficacy is difficult to demonstrate.
gether with the huge costs involved in bringing new drugs to The FDA approved a cholesterol-lowering agent in 2002 after a
the market. It is predicted that between 2007 and 2012, $ 67 small number of clinical trials, which included 3,900 patients!
billion will be lost from the top pharmaceutical companies in In the absence of proven efficacy against heart attacks the drug
the USA. earned billions of dollars for the company, presumably due to
the robust advertising campaign. We would all agree (as men-
Greaves pointed out that 'conflicts of interest' occur when indi- tioned in a previous newsletter) that all clinical trials should be
viduals have material gains, irrespective of financial value, that registered and the results, whether favourable or not, be made
could influence or be perceived as influencing their opinions, available to the public.
decisions or actions in relation to patient care or the conduct of Finally I am always intrigued by serendipity, especially in medi-
research. Potential conflicts have happened to all of us in the cine. Although we live in an age of ‘certainty’ and people speak
form of hospitality, attendance at conferences, and gifts, al- about focused research, it remains that many great medical
though we always claim that our judgement is not affected. A developments still happen by chance and hopefully will contin-
more difficult situation arises with clinical trials, especially in ue to do so in the future.
Europe. Because of difficulties with cost and indemnity, the
number of ‘investigator-led trials’ has decreased and the num- Shaun Mc Cann
ber of industry sponsored trials increased. Coupled with this is Editor in Chief
the payment for enrolling patients in industry-led tri-
als. It must be remembered, however, that Health
Services do NOT provide much support for conferenc-
es and even light lunches at clinical meetings are
provided by industry in many hospitals. The industry
invests large amounts of money supporting educa-
tion, bringing new treatments to the attention of doc-
tors and supporting biomedical research. Educational
support is commonly in the form of an unrestricted
grant but industry sponsored clinical trials are more
likely to be associated with positive outcomes than in-
vestigator–led trials. Hopefully, a change in legisla-
tion in Europe will make investigator–led trials easier
to conduct without endangering the public.
Although we must work together, it behoves the med-
ical profession to be advocates for their patients. The
regulatory bodies are constantly criticised, not always
justifiably. If they are too cautious the public becomes
upset by delays in introducing new agents, which may

6 > EHA Newsletter November 2008


Spotlight on Scientific Working Groups
In 2008, EuroFlow was launched as the latest addition to the EHA Scientific Working Groups (SWG’s), bringing the total

number of groups to eleven. The main objectives of the EHA Scientific Working Groups are to create scientific networks

that both promote high quality science during the annual congress and attract basic scientists to meetings. To complete

the picture of SWG’s - some of whom featured in earlier issues of the Newsletter - we high-light the recent activities of

five of the groups.

Scientific Working Group on Granu- fining various B-cell compartments that group and the BIOMED-2 Concerted
locyte and Monocyte Disorders may carry early clonal characteristics. Action group, the European Study Group
Surinder Sahota (Southampton, UK) de- on MRD-detection in ALL (ESG MRD-
>  The EHA SWG on granulocyte and scribed molecular approaches to track ALL) has provided a framework for stan-
monocyte disorders was established in the myeloma compartment and identify dardizing, improving and comparing
2005 during the 10th EHA Congress in distinct profiles for pre-plasma cells that molecular MRD-diagnostics using Ig/
Stockholm, Sweden. The main goal is to may belong to the myeloma clone. Pieter TCR-gene rearrangements as RQ-PCR
promote co-operation between clinicians Sonneveld presented gene expression targets. Through 13 quality control
and scientists involved in basic, transla- data of myeloma patients, introducing ‘rounds’ with subsequent problem reso-
tional and clinical research in the field of the concept of undertaking molecular lution meetings, common guidelines
granulocyte and monocyte disorders. Un- profiles of chemo resistance in myeloma have been developed regarding both
der this remit, scientific sessions during stem cells. Finally, Karin Vanderkerken technical aspects and issues regarding
the 13th EHA Congress, covered topics on (Brussels, Belgium) presented data of interpretation of data (see: Van der
clinical and molecular diagnosis of neu- the 5TMM myeloma mouse model, which Velden et al., Leukemia 2007;21:604-
tropenias and unknown aspects of the serves as a pre-clinical model for my- 611). At the same time, the group has
role of neutrophils in innate immunity, eloma (stem-) cell analysis. grown, now representing nearly 40 lab-
stimulating interesting discussions in the oratories from Europe, Asia and Austra-
audience that included for the first time Pieter Sonneveld, Chair lia, with its remit extended to cover
clinicians, basic scientists and trainees Erasmus Medical Center, Rotterdam, MRD-diagnostics in malignant lympho-
in hematology. In addition, a major high- The Netherlands ma. The ESG MRD-ALL SWG, provides a
light for the year was the 3rd Neutropenia framework for clinical study groups who
Network Conference, that took place in want to use MRD diagnostics within
Crete, Greece, September 26-27, 2008, Scientific Working Group: The their treatment protocols.
under the auspices of EHA and covered European Study Group on MRD-
acquired and congenital neutropenias in Detection in ALL (ESG MRD-ALL) Thorsten Raff, Chair
a clinical, laboratory, cellular, and mo- University Hospital Schleswig Holstein, Kiel,
lecular biology settings. >  Originating from a group of 15 Germany
MRD-laboratories from the I-BFM study
Helen Papadaki, Chair
University Hospital of Heraklion, Heraklion
Crete, Greece The current EHA Scientific Working Groups are:

Scientific Working Group 1: Chronic Myeloid Leukemia


Scientific Working Group on Mul- Scientific Working Group 2: Granulocyte and Monocyte disorders
tiple Myeloma Scientific Working Group 3: Multiple Myeloma
Scientific Working Group 4: Myelodysplastic Syndromes
>  At the 13th Congress of the Europe- Scientific Working Group 5: Myeproliferative Disorders
an Hematology Association, the SWG on Scientific Working Group 6: Quality of Life and Symptoms
Multiple Myeloma hosted a scientific Scientific Working Group 7: Thrombocytopenias
meeting, “The Myeloma Stem Cell” Scientific Working Group 8: ESG-MRD-ALL
chaired by Pieter Sonneveld (Rotterdam, Scientific Working Group 9: Pharmacokinetics, pharmacogenetics &
the Netherlands) and Hans E Johnsen pharmacodynamics
(Aalborg, Denmark). First, Hans E Johns- Scientific Working Group 10: Red Cell and Iron
en introduced the concept and scientific Scientific Working Group 11: EuroFlow
background of the myeloma stem cell,
while Martin Perez Andres (Salamanca, To find out more about the Scientific Working Groups, check our website at:
Spain) addressed the B- cell hierarchy in www.ehaweb.org
B-cell malignancies and myeloma, de-

EHA Newsletter November 2008 > 7


SWG chairs meeting: T Raff, C Camaschella, M Hasan, U Jäger, H Pahl and J van Dongen

Scientific Working Group on Phar- Scientific Working Group Euro- close collaboration between industry and
macokinetic, Pharmacodynamic Flow: Flow cytometry for fast and academia. The EuroFlow consortium con-
and Pharmacogenetic sensitive diagnosis and follow-up sists of two SME’s and ten diagnostic re-
of haematological malignancies search groups, composed of experts in
>  Chemotherapy – despite intensive the fields of flow cytometric and molecu-
research to find more specific treatment >  Laboratory diagnostics of hemato- lar diagnostics.
to target tumour cells - remains the logical malignancies has three major ap-
corner stone of the majority of hemato- plications: establishing diagnosis, prog- The EuroFlow Consortium is developing
logical protocols. Most treatment proto- nostic classification, and evaluation of new software for fast and easy handling
cols today are empirical and based on treatment effectiveness. While molecular of large data sets and for integration of
clinical experience. Despite long clinical techniques have brought new insights into eight -color stainings into a single multi-
use, little information is available about classification and monitoring of treatment color data file; standardization of eight
the mechanisms of action, individual- effectiveness, they are frequently time -color immunostaining protocols for fast
ization of those factors affecting thera- consuming (taking two to three days), not and easy flow cytometric diagnosis and
peutic efficacy and last but not least, in- applicable for all patients, and unable to classification of hematological malig-
teractions with other drugs. focus on cellular subpopulations without nancies (as well as evaluation of treat-
The Pharmacokinetic, Pharmacody- prior purification. Flow cytometric immu- ment effectiveness); multiplex immuno-
namic and Pharmacogenetic SWG aims nophenotyping is the sole technique ful- bead assays for detection of fusion
to improve understanding of the mech- filling requirements of high speed, broad proteins and oncoproteins per disease
anisms of action of cytostatic drugs, to applicability at diagnosis and during fol- category (particularly ALL and AML); and
establish data-bases for EHA mem- low-up, and accurate focusing on malig- software for automated pattern recogni-
bers, to organize and design random- nant cell populations using membrane- tion of normal, reactive, and aberrant
ized PK/PD multi-centre studies, to bound and intracellular proteins as (malignant) leukocyte populations in
provide help in designing and coordi- targets. Innovations are needed in flow blood and bone marrow. In addition, we
nating studies and to introduce thera- cytometry, such as development of novel are looking to create large data bases
peutic drug monitoring and dose ad- antibodies, novel immunobead technolo- with 100s of well-defined normal, reac-
justment to optimize individual gy, eight-color immunostaining protocols, tive and malignant cell samples, which
chemotherapy treatment. The hope is and novel flow cytometry software for fast can be used as ‘templates’ for fully auto-
that implementation of PK/PD/PG and easy interpretation of complex data mated comparisons with patient sam-
knowledge of cytostatics will ultimately and for automated pattern recognition, all ples. As soon as the projects have been
improve treatment strategies and pa- of which are key objectives for the Euro- completed and approved, the results will
tient outcomes. Flow consortium (EU-FP6 project LSHB- be shared at Scientific Working Group
CT-2006-018708). This needs a multidis- sessions of the annual EHA meetings.
Moustapha Hassan, Chair ciplinary translational research approach
Karolinska University Hospital, Stockholm, using cutting edge technologies and bio- J van Dongen, Chair
Sweden logical data arising from genomic re- University Medical Center, Rotterdam,
search, which can be addressed best via The Netherlands

8 > EHA Newsletter November 2008


Young investigator award to study CDX2 in AML
Stefan Fröhling: Winner of the EHA José Carreras
Foundation Young Investigator Fellowship 2008
>  It is a great honor for me to be the knowledge about the normal functions of
recipient of this year’s EHA José Carre- CDX2, other gene products that mediate
ras Foundation Young Investigator Fel- the leukemogenic effects of CDX2, in-
lowship, particularly given the high stan- cluding potentially therapeutic mole-
dard of previous beneficiaries as well as cules, are not known.
the high quality of the applications con-
sidered this year. A particularly enticing aspect of these
observations is that aberrant expression
I first learned about the EHA Fellowship of CDX2 appears to affect the majority of
Program in 2002 when I attended the 7th AML patients. Thus, understanding
Congress of EHA in Florence. Since that W Fibbe presents Stefan Fröhling with the award mechanisms of transformation mediated
time, I have been appreciative of the ef- by CDX2 are likely to be of value for the
forts made by the EHA in promoting the career development of broad spectrum of AML, and not solely for selected genetic or
young scientists involved in hematologic research. morphologic subtypes. Furthermore, although it is challenging
to target transcription factors therapeutically, evolving tech-
My application for an EHA Fellowship was motivated by a com- nologies may enable novel approaches for treatment. For ex-
bination of factors. First, based on the excellent track record of ample, large-scale RNA interference (RNAi) screens for syn-
past recipients, I realized that an EHA Fellowship provides a thetic lethal interactions, and unbiased small-molecule
superb platform for young investigators to pursue a career in screens have potential to identify compounds or pathways that
academic hematology. Second, I was encouraged to apply for will effectively target CDX2 overexpression in AML.
an EHA Fellowship by my academic mentors, Prof Hartmut
Döhner from my home institution (University Hospital of Ulm, The goals of my project are to characterize the transcriptional
Germany) and Dr Gary Gilliland (Harvard Medical School, Bos- changes induced by ectopic expression of CDX2 in hematopoi-
ton, USA), my current supervisor. Lastly, during my postdoc- etic stem and progenitor cells in vitro. Another goal is to deter-
toral fellowship, I had the privilege of working with Dr Brian mine the gene-expression profiles of murine leukemias in-
Huntly (Cambridge Institute for Medical Research, UK), who duced by ectopic expression of CDX2 in hematopoietic stem
had received the EHA José Carreras Foundation Young Investi- and progenitor cells in vivo. Furthermore to determine the
gator Fellowship in 2005. During my time with Brian, I learned transcriptional changes associated with genetic inhibition of
about the many advantages of an EHA Fellowship, both the fi- CDX2 in human AML cell lines and to identify candidate down-
nancial support, as well as the opportunity to become part of stream effectors of aberrant CDX2 expression in myeloid leu-
the European hematology community. kemogenesis through bioinformatic analyses, cross-species
comparisons, and integration of the results from experimental
My EHA José Carreras Foundation Young Investigator Fellow- models of hematopoietic transformation with gene-expression
ship will be used to study the role of the homeobox transcrip- profiles and clinical data from patients with AML. Lastly we
tion factor CDX2 in the pathogenesis of acute myeloid leukemia want to experimentally validate candidate downstream effec-
(AML). In a collaborative project between my home institution tors of aberrant CDX2 expression in myeloid leukemogenesis.
and the Gilliland Laboratory at Harvard University, it was previ- Longer-term ambitions include a genome-wide RNAi-based
ously discovered that the CDX2 gene was expressed in the leu- functional genetic strategy to identify genes that are essential
kemic cells from the majority of adult patients with AML, for the viability and proliferation of leukemic cells specifically
whereas CDX2 expression was undetectable in the normal in the context of aberrant CDX2 expression.
adult hematopoietic compartment. Furthermore, we and oth-
ers have demonstrated the functional relevance of aberrant The generous funding provided by the EHA José Carreras
CDX2 expression in a series of in vitro and in vivo experiments. Foundation Young Investigator Fellowship is of critical impor-
For instance, CDX2 enhanced the capacity of myeloid progeni- tance for the realization of these goals. More broadly, I believe
tor cells to self-renew, an important functional attribute of that initiatives like the EHA Fellowship Program will encourage
most, if not all, AML subtypes, suggesting that CDX2 may be a young investigators, especially those who are trained as physi-
common downstream effector of different leukemogenic path- cians, to commit themselves to a career in hematologic re-
ways. Expression of CDX2 led to dysregulation of Hox genes, search.
known transcriptional targets of CDX family members during
development, supporting a potential role of CDX2 in the devel- Stefan Fröhling
opment of human AML with aberrant HOX gene expression. Winner of the EHA José Carreras Foundation Young Investigator
Since the consequences of aberrant CDX2 expression have not Fellowship 2008
been studied using unbiased approaches that require no prior University Hospital of Ulm, Germany

EHA Newsletter November 2008 > 9


Wine and health:
End of Road for French Paradox?
Giovanni Morelli, EHA's resident wine authority, updates us on the resveretrol

heart health story, and delivers a mixed bag of news for wine lovers. A

decline in wine consumption in France and craving for fast food is being

balanced by EU initiatives to expand production of quality wine.

>  The wine industry extols the merits four glasses of red wine daily), fulfills the
of drinking wine, and we all marvel at the definition of a dietary compound that
proposed health benefits. We mentioned mimics some aspects of calorie restric- Wine tasting can be fun unless taken too seriously!
the possible benefits of resveretrol in tion. Some may feel three to four glasses
previous newsletters but decided that of wine daily to be excessive and that but the wine business is not immune
the amount of wine required daily to pro- perhaps one or two glasses of wine sup- from controversy. In Montalcino, that
vide a protective effect would probably plemented with oral resveretrol would do most beautiful of hill towns in Tuscany,
induce severe liver damage, thereby ne- the trick. their high priced Brunellos have come
gating any putative benefit. However A lot of this type of research is based on under scrutiny. The public prosecutor in
things might be getting better! In a study, the so-called 'French paradox'. However Siena, Nino Calabrese, is investigating
published by Richard Weindruch and col- the bad news is that the French are re- famous names including Frescobaldi and
leagues, from the University of Wiscon- ducing their intake of red wine and tak- Banfi for possibly using grapes other
sin-Madison, (PloS ONE 2008:3: e2264) ing to fast-food. Yes, less than 50 percent than Sangiovese or importing grapes
they claimed that mice given low dose of young people in France are drinking from other areas. In the US billionaire
resveretrol were protected from heart wine and only 10 percent consume it wine collector, William Koch - no rela-
disease. They report that low dose resv- regularly! In 1980 the average consump- tion as far as I am aware to Robert Koch
eretrol inhibits gene expression profiles tion of wine in France was 120 liters per who in 1890 established the etiology of
associated with cardiac and skeletal year and this has fallen by 50 percent. Anthrax and Tuberculosis - found that
muscle aging, and prevents age-related Paradoxically wine drinking in America wines that he had bought were not in fact
cardiac dysfunction. Dietary resveretrol in the 21 – 29 year age group is the most part of Thomas Jefferson’s collection as
also mimics the effects of calorie restric- rapidly growing segment of the world he had been led to believe! He paid a
tion in insulin mediated glucose uptake market. large amount of money for his mistake!
in muscle. Gene expression profiling What is more worrying is the loss of eat-
suggests that resveretrol may retard ing habits and the craving for fast foods. There is a huge surplus of wine (mostly
some aspects of aging through altera- The number of family meals and busi- poor quality) in Europe today, illustrated
tions in chromatin structure and tran- ness lunches has decreased by 50 per- by the fact that in 2006 the EU spent € 2
scription. Resveretrol, at doses that can cent in the last 10 years in France and billion distilling surplus wine into indus-
be readily achieved in humans (three to obesity is on the increase. Diana Macle trial alcohol! Marianne Fischer Boel, EU
writing in the Wine Spectator quotes agriculture commissioner, is trying to
Professor Francois d’Hauteville as say- help by convincing small growers to re-
ing: ‘The young people I interviewed rec- tire and pull out 400,000 acres of vines
ognized that wine was part of French and subsequently to phase out distilla-
culture and identity but they know very tion subsidies. Michael Mann, spokes-
little about it, and many didn’t even like man for the EU agriculture and rural de-
the taste!' Perhaps the French Paradox velopment department, is quoted as
will become a thing of the past. saying: ‘In the short term production will
Another interesting use of resveretrol is decrease but when planting restrictions
in the treatment of MELAS. This syn- go, there is no reason why production of
drome, characterized by mitochondrial quality wine should not expand’. For both
myopathy, encephalopathy, lactic acido- our heart health and drinking pleasure,
sis and stroke-like episodes, is caused let us hope that both Weindruch and
by mitochondrial dysfunction and is cur- Mann prove correct.
rently undergoing a randomized trial us-
ing resveretrol (STR501) as a mitochon- Giovanni Morelli
drial stimulant!
As physicians we all have become aware Giovanni Morelli is a hematologist who divides
All grapes are green in the beginning of a number of drug scandals recently, his time between Dublin and Tuscany

10 > EHA Newsletter November 2008


The Scientific Program Committee (SPC)
and SPC Advisory Board (SPC AB):
how does it work?
Preparations for the 14th EHA congress, to be held in Berlin, Germany (June 4-7, 2009) are now full steam ahead. For

every congress, the EHA Board appoints a Scientific Program Committee (SPC), whose role is to compose a program for

the annual congress that meets the highest scientific and educational standards. The SPC is supported by members of

the EHA Executive Office under the lead of Rik Craenmehr, who serves as the Congress Assistant, with the remit of

assuring an efficient and reliable organization.

ment of educational activities outside the annual congress. Fi-


nally, one member of the SPC is responsible for maintaining
the database of abstract reviewers. This database is checked
annually for accuracy, areas of expertise and balance with re-
spect to gender and nationality of reviewers.

How do SPC and SPC AB work?


The SPC will receive support from the SPC-AB, which submits
suggestions for the invited speakers program and contributes
to selecting the abstracts for presentation at the congress. The
SPC-AB consists of 20-25 members, who serve for 1-2 years
and are eligible to serve on the SPC.
Every year, about 12 members rotate off the SPC-AB and 12
new members are appointed. The SPC-AB should be balanced
for the different areas of expertise, stages of career, gender,
and nationality. The EHA Board approves and appoints the
SPC-AB, after receiving suggestions by the SPC chair.

The Scientific Program Committee and the Advisory Board


have two principal tasks. One is to choose the invited speakers
and their topics.
Radek Skoda Both members of SPC and SPC AB are expected to submit pro-
posals. The proposals are collected in August and discussed
>  SPC member by appointment during the meeting of the SPC in September. A selection of top-
First some background information. The SPC consists of 10 full ics and speakers is made during this meeting and the program
members who are appointed by the EHA-Board. The Congress is prepared and finalized during the last months of the year.
President serves as the 11th member of the SPC for one year.
All other SPC members serve for two years, except for the SPC The second task of the SPC and SPC-AB members is to review
chair, who serves for three years. The chair of the SPC is ap- submitted abstracts and to select abstracts for poster or oral
pointed by the Executive Board as chair of both the SPC and presentation. This takes place during a meeting in the first
the SPC Advisory Board (SPC-AB). The SPC is responsible for week of April 2009. I would like to encourage you and your col-
the important task of putting together the scientific and educa- leagues to submit abstracts for EHA-14. Please remember that
tion program for the entire EHA Congress. there are up to 80 travel grants that are assigned in the order
of the ranking that an abstract receives. In previous years all
Every year one former chair and 3-4 full members rotate off abstracts selected for oral presentation and a substantial num-
the SPC and are replaced by the EHA-Board. The 10 full mem- ber of posters received a travel grant. The deadline for abstract
bers of the SPC should cover the entire field of hematology. A submission is March 1, 2009.
minimum of two full members of the SPC should also be mem-
bers of the EHA Board and at least one full member of the SPC I look forward to seeing you in Berlin!
is also member of the EHA Education Committee to ensure co-
ordination between the activities of the two committees. The Radek Skoda, SPC Chair for EHA-14
EHA Education Committee is primarily involved in the develop- University Hospital Basel, Switzerland

EHA Newsletter November 2008 > 11


Copenhagen hosts 13th EHA Congress
The 13th Congress of the European Hematology Top Top 10 countries:
10 countries: registrationsregistrations
2008: 2007:
Association (EHA) in Copenhagen (June 12-15, 2008) • Italy 680 474
• United Kingdom 453 349
will be remembered as yet another successful event in • France 455 390
• Greece 383 317
the annals of EHA congress. • Spain 364 300
• United States of America 337 214
The meeting attracted over 6600 delegates from 103 • Germany 329 277
• Switzerland 216 214
countries, who enjoyed a wide ranging scientific • The Netherlands 213 180
• Denmark 181 88
program of the highest quality.
WWW.EHAWEB.ORG

>  Altogether nearly 1800 abstracts were submitted. During


the Presidential Symposium the five best abstracts were pre-
sented and 80 oral presenters were awarded with travel grants
of € 500 and free congress registration. Once again, the red-
capped EHA ‘poster walkers’ proved a popular draw, encour-
aging lively discussions among interested delegates.

Two outstanding hematologists were honored in Copenhagen.


The EHA José Carreras Award was made to Professor John
Goldman (Imperial College London, United Kingdom), while
Professor Dieter Hoelzer (University Frankfurt, Germany) re-
ceived the EHA Jean Bernard Lifetime Achievement Award.
EHA-CME desks

Professor Goldman has played an important role in one of the


major success stories of leukemia therapy, with his work con-
tributing to the fact that chronic myeloid leukemia (CML) pa-
tients can now hope to live normal life spans.
Professor Goldman was a pioneer in the use of bone marrow
transplants in CML, a therapy that became the standard of care
for two decades. In the late 1990s, when new drugs were de-
veloped to block the effects of the genetic changes causing
CML, Professor Goldman led the efforts to develop new tech-
nologies to detect residual levels of CML.

Professor Hoelzer, head of the Institute for Hematology at the


University of Frankfurt am Main, has contributed to many of
the recent advances in treatment of adult acute lymphoblastic
leukemia (ALL).
Bella Center in Copenhagen, Denmark
He set up a cross-German study group involving more than 100
Registrations 1994-2008 hospitals to examine therapies and their effectiveness in treat-
6672 ment of ALL, at a time when the disease had a cure rate of less

Registrations per continent


than 10 percent. The study group contributed to substantial
7000
7000

6000
6000

Registrations per continent


5000
5000
81%
4000
4000
Europe
3000
3000 Asia
North America
2000
2000
South America
1000
1000 Australia

7% Africa
00 5%
1s
1s tt 2nd
2nd 3rd3rd 4th 4th5th 5th
6th 7th
6th 8th
7th 9th8th 10th 9th11th 10th
12th 11th
13th 3% 1% 3%

12 > EHA Newsletter November 2008


WWW.EHAWEB.ORG
Abstracts 1996-2008

1892
2000

1800

1600

1400

1200

1000

800

600

400

200
The poster area attracted many visitors
0
2nd 3rd 4th 5th 6th 7th 8th 9th
WWW.EHAWEB.ORG 10th 11th 12th 13th

improvements in the diagnosis of ALL and the development of


targeted, therapies. Tailored therapy for ALL is very important
as 95 percent of people with the disease show individual pat-
terns in their leukemic cells. This individualized approach,
which Professor Hoelzer championed, has resulted in cure
rates for ALL of 50 percent .

The EHA-ASH policy forum in Copenhagen titled ‘Relation be-


tween academia and pharma: public trust at stake?’ focused
on good governance. Both EHA and American Society of Hema-
tology (ASH) have long standing, good relations with the phar-
maceutical industry, which remains crucial for the core activi-
ties of both associations.
M Greaves at the EHA-ASH policy forum
The Molecular Hematopoiesis Workshop was organized for
the second year running. Following last year’s success a big- ganizers (Tariq Enver, Tony Green, Dan Tenen and Ivo Touw)
ger room was allocated and again the room was filled to ca- an exciting addition has been made to regular congress edu-
pacity with enthusiastic delegates. The aim of this workshop cational sessions. The meet-the expert sessions were suc-
is to present cutting edge hematological science in a new and cessfully moved to lunch hours, with participants appreciat-
dynamic way. Thanks to the efforts of both speakers and or- ing the interactive opportunities they provided.

Exhibition area

The EHA booth in the Center Hall N Borregaard, Congress President

EHA Newsletter November 2008 > 13


Abstract
Abstract selection
selection
13th 13th Congress
Congress in Copenhagen
in Copenhagen
Top 10Top 10 countries:
countries: abstracts abstracts Abstracts selection 13th Congress in Copenhagen
2008: 2007:
145 Oral Oral
274 274 145
• Italy 369 299
• Spain 131 146 Poster Poster

• Greece 102 115


• United Kingdom 101 114 488 488 PublicationPublication
Only Only
884 884
• Germany 99 134
Rejected Rejected
• France 76 103
• United States of America 84 62 It is our privilege to express our gratitude to the sponsors of
• Czech Republic 74 74 the meeting, the Scientific Program Committee, the Advisory
• Romania 60 39 Board, the Local Organizing Committee, EHA Board and Exec-
• The Netherlands 58 24 utive Office and all the individuals who worked so hard to make
WWW.EHAWEB.ORG
WWW.EHAWEB.ORG
the 13th Congress of EHA a resounding success.
The 13th Congress also providedWWW.EHAWEB.ORG
a platform for European working
groups and network meetings. Besides scientific sessions there Niels Borregaard Gilles Salles
were also many other possibilities to meet, including the social Congress President Chair Scientific Program Committee
evening, the Farewell Lunch, the
Participation exhibition
devided by age and poster sessions. 13th Congress 13th Congress

Participation divided by age


1920-1930
1961-1970
1951-1960
33% 1931-1940
34%

1941-1950

1951-1960

1961-1970

1941-1950 1971-1980 1971-1980


11% 1931-1940 1981-XXXX 19%
1% 1920-1930 1% 1981-XXXX
1%

WWW.EHAWEB.ORG D Hoelzer receives the Jean Bernard Lifetime Achievement Award

Nearly all the sessions were webcasted

14 > EHA Newsletter November 2008


Collaboration between EHA and the
European School of Haematology (ESH)
EHA and the European School of Haematology (ESH) have collaborated on several projects in the past. In February 2008

the Joint Executive Committee was established to formalize the collaboration for future events and new projects. The

committee representing both organizations includes W Fibbe, R Foà, E Gluckman and B Löwenberg. Selection of topics

for workshops and development of new initiatives are amongst the most important tasks of this committee.

>  Scientific workshops are smaller scale meetings on dedi- ESH-EHA Joint Activities in 2009
cated topics of relevance for hematology. They are intended to ESH-EHA Scientific Workshop: Leukemic and Cancer
promote informal interaction and discussion between scien- Stem Cells
tists and clinicians working in the field. Another part of joint April 3-5, 2009, Mandelieu, France
projects are the interactive hematology tutorials. Hematology Chairs: C Chomienne, D Bonnet, P Valent and D Louvard
tutorials are annual courses aiming to provide laboratory and ESH-EHA Hematology Tutorial: Hematology Tutorial
clinical hematologists with an integrated diagnostic and clini- on Lymphoid Malignancies
cal work-up of hematological disorders. May 15 - 17, 2009, Tallinn, Estonia
Chairs: R Foà, E Kimby and G Zini
A new logo was designed to give ‘face’ to the new style collabo- ESH-EHA Scientific Workshop: Innovative Therapies
ration. for Red Cell and Iron Related Disorders
Hema
tology A
sso
November 6 – 8, 2009
n
ea cia Coordinators: Y Beuzard and C Camaschella
op t
ESH-EHA Annual Diagnostic Workup of
r

ion
Eu

Hematological Malignancies:
Focus on Chronic Diseases
atology

Autumn 2009
Chairs: B Bain, R Foà, G Zini
Haem
of

For information on the tutorials or


ol
ho

c workshops please visit: www.esh.org or


ea nS
Europ www.ehaweb.org

Tutorials are part of the joint activities by EHA and ESH.

EHA Newsletter November 2008 > 15


‘Letter to the Editor’
> The EHA Newsletter encourages its readers to share lished, please be sure to include your full name and accurate
their opinions through letters to the editor. contact information. Anonymous letters to the editor cannot be
We would like to hear your ideas on any topic in hematology. published.
We would also appreciate your views on the Newsletter, favor- E-mail us at p.stork@ehaweb.org
able or not!
Letters must be short (maximum of 300 words) and may be edited. The EHA Newsletter Editors
Shaun McCann
If you are interested in having your Letter to the Editor pub- Catherine Lacombe

Cover photographs
Please be encouraged to send in your scenic photographs for future newsletter covers (size: standing).
The EHA offers € 100 for the photograph chosen as cover photo, starting next issue.

November 2008 May 2008 November 2007 May 2007

Croatia United States Denmark Switzerland


Adriana Neghina (RO) Marc Rudoltz (USA) Martin Lorenzen (DK) Karin Amrein (CH)

EHA Members 3,000

Benefits of EHA Membership


- Subscription to Haematologica/ The Hematology Journal (impact factor 5.516)
- Reduction of € 180 on the individual registration fee for the EHA Annual Congress (junior members receive a reduction of
€ 105).
- Eligible to apply for EHA Research Fellowships & Grants
- Entitled to apply for a scholarship to attend ESH-EHA Scientific Workshops
- EHA Newsletter
- Access to the webcast of the EHA annual congress
- Access to the EHA membership database

16 > EHA Newsletter November 2008


Overview EHA Committees and Units
EHA CME Unit EHA Nomination Committee B Schlegelberger, Germany
F Lo Coco, Italy (Chair) I Pabinger, Austria (Chair) R Schlenk, Germany
D Loukopoulos, Greece A Biondi, Italy M Trneny, Czech Republic
J Musial, Poland M Björkholm, Sweden A Urbano Ispizua, Spain
A Prentice, United Kingdom B Löwenberg, The Netherlands A Waage, Norway
A Urbano Ispizua, Spain
EHA Corporate Sponsor Committee EHATol Unit
U Jäger, Austria (Chair) EHA Press Committee 2009 G Zini, Italy (Editor)
E Berntorp, Sweden A Hagenbeek, The Netherlands (Chair) B Bain, United Kingdom
H Döhner, Germany R. Hehlman, Germany W Erber, United Kingdom
I Touw, The Netherlands W Fibbe, The Netherlands R Foà, Italy
I Roberts, United Kingdom M Rozman, Spain
EHA Curriculum Committee R Skoda, Switzerland M van ‘t Veer, The Netherlands
E Hellström-Lindberg, Sweden (Chair)
L Degos, France EHA Publication Committee
C Hok Toh, United Kingdom W Fibbe, The Netherlands (Chair)
W Ludwig, Germany M Cazzola, Italy
P Rebulla, Italy R Foà, Italy
A Urbano Ispizua, Spain C Lacombe, France
S McCann, Ireland
EHA Education Committee
A Green, United Kingdom (Chair) EHA Scientific Program Committee
M Arat, Turkey 14th Congress (SPC)
E Berntorp, Sweden R Skoda, Switzerland (Chair)
C Chomienne, France H Büller, The Netherlands
C Craddock, United Kingdom C Chomienne, France
L Degos, France J Cools, Belgium
W Fibbe, Netherlands R Hehlmann, Germany (Congress
E Hellström-Lindberg, Sweden President)
D Jasmin, France F Lo Coco, Italy
F Lo Coco, Italy C Niemeyer, Germany
H Serve, Germany I Peake, United Kingdom
G Salles, France
EHA Fellowships and Grants S Thein, United Kingdom
Committee M Theobald, The Netherlands
C Lacombe, France (Chair)
C Camaschella, Italy EHA Scientific Program Committee
I Touw, The Netherlands Advisory Board 14th Congress
N Avent, United Kingdom
EHA Governance Committee M Baccarini, Italy
E Berntorp, Sweden (Chair) C Beamont, France
C Camaschella, Italy E Berntorp, Sweden
J Goldman, United Kingdom J Cornelissen, The Netherlands
U Jäger, Austria C Craddock, United Kingdom
E Montserrat, Spain N Cross, United Kingdom
T Enver, United Kingdom
EHA Local Organizing Committee C Gachet, Italy
14th Congress G Gaidano, Italy
R Hehlmann, Germany (Congress P Ghia, Italy
President) W Hofmann, Germany
B Dörken, Germany B Huntly, United Kingdom
D Niederwieser, Germany J Ingerslev, Denmark
E Thiel, Germany S Izraeli, Israel
B Lämmle, Switzerland
EHA Membership Committee L Malcovati, Italy
I Touw, The Netherlands (Chair) M Manz, Switzerland
M Guenova, Bulgaria R Pieters, The Netherlands
B Huntly, United Kingdom M Piris, Spain
I Roberts, United Kingdom J San Miguel, Spain

EHA Newsletter November 2008 > 17


Current members Upcoming
of the EHA Board Congresses
Willem Fibbe – President 2007 – 2009 – The Netherlands Berlin

Robin Foà – President Elect 2007-2009 – Italy

Eva Hellstrom-Lindberg – Past President 2007-2009 – Sweden

Hartmut Döhner – Treasurer 2009-2010 – Germany

Irene Roberts – Secretary 2006-2009 – United Kingdom

Erik Berntorp – 2005-2009 – Sweden

Clara Camaschella – 2007-2011 – Italy > 14th Congress of the EHA


Date: June 4-7, 2009
Christine Chomienne – 2007-2011 – France Place: Berlin, Germany
Congress President: Prof R Hehlmann
Ulrich Jäger – 2006-2010 – Austria

Catherine Lacombe – 2005-2009 – France

Jorge Sierra – 2008-2012 – Spain Barcelona

Radek Skoda – 2006-2010 – Switzerland

Ivo Touw – 2006-2010 – The Netherlands

Colophon > 15th Congress of the EHA  


The EHA Newsletter is published by the European Hematology Association Date: June 10 – 13, 2010
twice a year. Membership of the European Hematology Association includes Place: Barcelona, Spain
subscription to the EHA Newsletter. Congress President: Prof J San Miguel

Editors
Editor-in-Chief Shaun McCann
Editor Catherine Lacombe
Sub-editor Janet Fricker London
Editorial Coordination Ineke van der Beek

Photography & Illustrations


Cover Adriana Neghina MD, Romania
(Plitvice National Park – Croatia)
Congress photographs Moritz Wustinger
Cartoon Jim Cogan
Picture of tutorial Angela de Vlaming

Printing
Drukkerij BibloVanGerwen,
’s-Hertogenbosch > 16th Congress of EHA
Date: June 9-12, 2011
Contact editors Place: London, United Kingdom
For general remarks, questions and suggestions e-mail p.stork@ehaweb.org Congress President: Prof I Roberts

18 > EHA Newsletter November 2008


EHA Executive Office
Carin Smand Ineke van der Beek Djowrain Bouterse
Managing Director External Affairs Office Manager
National Societies

Rik Craenmehr Thom Annemiek Kuijsten


Congress Assistant Duyvené de Wit Annual Congress
CME Sponsor Program

Ans Steuten Liz Stokes Petra Stork


Executive Assistant to Publication &
Management Managing Director Communication
Fellowships &
Grants

Angela de Vlaming Victoria Zhuravleva


Membership Education

Contact Information

EHA Executive Office


Westblaak 71
3012 KE Rotterdam
The Netherlands

Phone +31 (0)10 4361 760


Fax: +31(0)10 4361 817
E-mail: info@ehaweb.org
Website: www.ehaweb.org

EHA Newsletter November 2008 > 19


the official newsletter for members of the EHA

Corporate
Sponsors 2008
Gold Sponsors

Bronze Sponsor

Contributors
EHA Executive Office
Westblaak 71
3012 KE ROTTERDAM
The Netherlands
T. +31 (0)10 436 17 60
F. +31 (0)10 436 18 17
E. info@ehaweb.org
W. www.ehaweb.org

Das könnte Ihnen auch gefallen